The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

6533b7d7fe1ef96bd1267c82

RESEARCH PRODUCT

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

Renato Costa Alessandra Murabito Vincenzo Tripoli Rossella De Luca Giuseppe Cicero

subject

0301 basic medicine Oncology Drug Radium-223 Male Cancer Research medicine.medical_specialty media_common.quotation_subject Antineoplastic Agents Bone Neoplasms Docetaxel 03 medical and health sciences Prostate cancer 0302 clinical medicine Quality of life Internal medicine medicine Humans media_common Aged Retrospective Studies Aged 80 and over Radioisotopes business.industry Bone metastasis Retrospective cohort study General Medicine Middle Aged medicine.disease Prostatic Neoplasms Castration-Resistant 030104 developmental biology Oncology Docetaxel Italy 030220 oncology & carcinogenesis Quality of Life Alkaline phosphatase Prednisone Taxoids Radium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Life business medicine.drug Radium

description

Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. Subjects and Methods: In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. Results: Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of R2 to 0.44 with a slope of 1.50 (p = 0.0021). Conclusions: Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients. Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment.

year	journal	country	edition	language
2017-12-15	Oncology

10.1159/000485102 https://pubmed.ncbi.nlm.nih.gov/29241166